The Chinese company is the earliest company who provides SARS-CoV-2 diagnostic kit based on PCR-Fluorescence Probing technology, which includes extraction and amplification reagents. It is designed to detect two targets of SARS-CoV-2 (ORF1ab and N gene).
In order to offer rapid test solution for SARS-CoV-2, the company independently developed fully automated nucleic acid extraction systems, portable molecule workstation (POCT) and real-time PCR, etc. and it also provides more than 2,200 types of testing services. Its solution has been serving more than 2,000 bench-marking medical institutions in China.
Further, the company's products and services covers molecular diagnostic reagents, nucleic acid diagnostic instruments, PCR laboratory solutions and Independent Clinical Laboratories (ICL) services.
To expand their market, the company is looking for partners in EU, the cooperation can be distribution agreement and commercial agency agreement.